Related Experiment Video
Updated: Aug 5, 2026
08:35
Production and Titering of Recombinant Adeno-associated Viral Vectors
Published on: November 27, 2011
New recombinant serotypes of AAV vectors
Guangping Gao1, Luk H Vandenberghe, James M Wilson
1Division of Medical Genetics, Department of Medicine, University of Pennsylvania School of Medicine, 2000, Translational Research Laboratories, 125S, 31st Street, Philadelphia, PA 19104-3403, USA. ggao@mail.med.upenn.edu
Current Gene Therapy
|June 25, 2005
Summary
Researchers discovered novel primate adeno-associated viruses (AAVs) that show improved gene transfer efficiency. These new AAV vectors offer enhanced performance for gene therapy applications, overcoming limitations of earlier AAV serotypes.
Area of Science:
- Molecular biology
- Virology
- Gene therapy
Background:
- Adeno-associated virus (AAV) vectors are used for stable gene transfer but face limitations in tissue tropism and transduction efficiency.
- Alternative AAV serotypes (e.g., AAV1, AAV4-6) have shown improved potency and broader tropism compared to the first used AAV serotype 2 (AAV2).
Purpose of the Study:
- To discover novel primate adeno-associated viruses (AAVs) with enhanced gene transfer capabilities.
- To evaluate the performance of vectors derived from these novel primate AAVs for gene therapy applications.
Main Methods:
- Molecular techniques were used to detect and isolate endogenous AAVs from human and non-human primate tissues.
- Phylogenetic and functional analyses were performed on the discovered primate AAVs.
- Vectors based on novel primate AAVs were evaluated in mouse models for tissue tropism and gene transfer potency.
Main Results:
- A family of 110 novel primate AAVs was discovered, prevalent in 18-19% of evaluated tissues.
- Primate AAVs segregated into clades with shared functional and serological properties.
- Vectors derived from novel primate AAVs demonstrated improved gene transfer to various tissues and achieved long-term phenotypic corrections in mouse and canine models.
Conclusions:
- Novel primate AAVs represent a promising source for developing next-generation gene transfer vectors.
- These new AAV vectors exhibit enhanced performance, potentially overcoming limitations of existing AAV-based gene therapies.
- Further development of these vectors could significantly advance gene therapy applications.
